MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the partnership with Berry Genomics, headquartered in the People’s Republic of China.
Personalis will be expanding business operations in the People’s Republic of China in 2020, and plans to form a wholly-owned subsidiary in Shanghai. The expansion will include building out a laboratory operation for local customers to use its ImmunoID NeXT PlatformTM, a commercial team to support local customers, and general and administrative functions.
Under terms of the agreement, Berry Genomics will provide Personalis certain services and local support.
“I’m pleased to be able to announce our partnership with the highly regarded Berry Genomics, headquartered in the PRC,” said John West, Chief Executive Officer. “Having achieved a high degree of scale in our Menlo Park, CA operation, we are poised to expand globally and entering into a partnership with a company that has the track record and capabilities of Berry Genomics will help us accelerate the ramp-up of our operation. Both companies have benefited from experience founded in the origin of next generation sequencing, and together we will take it even further.”
“We are excited to partner with Personalis, who is very well known for transforming the development of next-generation cancer therapies by providing more comprehensive molecular data,” said Dr. Daixing Zhou, Chief Executive Officer of Berry Genomics. “We have been focusing on disease detection and elucidating underlying molecular mechanisms. This partnership will serve the pharmaceutical community and ultimately enable them to develop better therapeutics, a natural extension of our current business.”
About Berry Genomics
Founded in May 2010, Berry Genomics is a leading company in clinical genomics and life science in China. Berry Genomics is dedicated to research, development and commercialization of genetic test technologies in clinical applications. Berry Genomics aims to assist accurate diagnosis of diseases throughout the full human life circle, and to improve human health. As a company with strong R&D capability, Berry Genomics pioneered the first NGS-based genetic test, NIPT, in China back in 2010. The company currently provides NGS-based tests for many genetic diseases and cancers from preconception to adulthood. Berry Genomics has around 1500 employees dedicating to developing products and providing services for over 4000 organizations and facilities home and abroad, including hospitals, research institutions, universities and corporations. Berry Genomics has been listed on A-share market in China since 2017 under the stock code: 000710. For more information, please visit https://www.berrygenomics.com.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis ImmunoID NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward Looking Statements
This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. For example, forward-looking statements include statements regarding the timing and results of Personalis’ expansion into the People’s Republic of China and elsewhere internationally, the results of the partnership between Personalis and Berry Genomics, and other future events. These forward-looking statements are subject to risks and uncertainties, including those related to the evolution of cancer therapies and market adoption of our services, our ability to serve the Chinese market, our expectations regarding future performance, and the COVID-19 pandemic, as well as other risks and uncertainties discussed in Personalis’ filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Forms 10-K and 10-Q and subsequent filings and in the documents incorporated by reference therein, all of which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. Except as otherwise required by law, Personalis disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
